Histogen Inc. (NASDAQ:HSTO) Sees Large Drop in Short Interest

Histogen Inc. (NASDAQ:HSTOGet Free Report) saw a large drop in short interest in August. As of August 31st, there was short interest totalling 40,200 shares, a drop of 26.9% from the August 15th total of 55,000 shares. Based on an average trading volume of 52,700 shares, the short-interest ratio is presently 0.8 days. Currently, 1.0% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Histogen stock. Renaissance Technologies LLC increased its stake in Histogen Inc. (NASDAQ:HSTOFree Report) by 78.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,167,067 shares of the company’s stock after purchasing an additional 514,387 shares during the period. Renaissance Technologies LLC owned 2.34% of Histogen worth $292,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 3.55% of the company’s stock.

Histogen Stock Down 4.3 %

NASDAQ:HSTO traded down $0.03 during mid-day trading on Monday, reaching $0.65. The stock had a trading volume of 126,433 shares, compared to its average volume of 388,669. Histogen has a 1-year low of $0.58 and a 1-year high of $1.81. The stock’s 50 day simple moving average is $0.73 and its two-hundred day simple moving average is $0.86.

Histogen (NASDAQ:HSTOGet Free Report) last issued its earnings results on Thursday, August 10th. The company reported ($0.49) EPS for the quarter. Histogen had a negative return on equity of 100.56% and a negative net margin of 63,799.99%. The firm had revenue of $0.01 million during the quarter.

About Histogen

(Get Free Report)

Histogen Inc, a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases.

Recommended Stories

Receive News & Ratings for Histogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogen and related companies with MarketBeat.com's FREE daily email newsletter.